Nektar (NKTR) Insider Tax-Sale of 725 Shares; 16,666 Options Reported Vested
Rhea-AI Filing Summary
Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics (NKTR), reported transactions on 08/19/2025. He sold 725 shares to cover tax withholding from RSU vesting at a weighted average price of $26.59 (trades ranged $26.19–$27.15). After that sale he beneficially owned 19,668 shares. The filing also reports an acquisition/vesting event for 16,666 stock options (exercise price $0.50) recorded as acquired on 08/19/2025; those options correspond to 16,666 underlying common shares and are shown as directly beneficially owned following the transaction. The filing notes a one-for-fifteen reverse stock split effective 06/08/2025 and explains the option grant and vesting timing from the 12/13/2023 award.
Positive
- Transparency: Filing discloses weighted average sale price and offers to provide full trade details upon request.
- Compensation alignment: Vesting and option grant details show continued equity-based alignment with management.
Negative
- Limited market signal: Sale was for tax withholding, not necessarily liquidity planning, which provides limited insight into insider sentiment.
Insights
TL;DR: Insider sold a small number of shares to satisfy tax withholding after RSU vesting and recognized newly vested options; ownership remained substantial.
The sale of 725 shares appears to be a non-discretionary sale to satisfy tax obligations tied to RSU vesting rather than a market-timed disposition. The weighted average sale price was reported as $26.59 with trades between $26.19 and $27.15. The report also records the vesting/event that resulted in 16,666 stock options being reported as acquired on 08/19/2025, with an exercise price of $0.50 and 16,666 underlying shares listed as directly owned following the transaction. The filing discloses the company’s 1-for-15 reverse split effective 06/08/2025, which adjusted reported amounts. For investors, this is a routine Section 16 reporting of compensation-related transactions rather than a signal of corporate change.
TL;DR: Transaction is compensation-related; documentation clarifies tax withholding sale and vesting, consistent with internal equity plan mechanics.
The Form 4 documents a tax-withholding share sale tied to RSU vesting and the satisfaction of performance-based vesting for options granted in 2023. The filer states the performance condition was certified on 07/17/2025 and options vested on 08/19/2025 subject to time-based vesting. The reporting is transparent about the weighted average sale price and offers to provide detailed trade-by-trade information if requested. This is standard practice under equity compensation programs and complies with disclosure expectations under Section 16.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 16,666 | $0.00 | -- |
| Sale | Common Stock | 725 | $26.59 | $19K |
Footnotes (1)
- Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $26.19 to $27.15 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. These stock options were granted on December 13, 2023 under the 2017 Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of three years from the date of grant. The Organization and Compensation Committee of the Board of Directors of the Issuer determined on July 17, 2025 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on August 19, 2025 (subject to remaining time-based vesting requirements).
